Cisplatin Ebewe

Cisplatin

Monotherapy or as part of existing chemotherapy for advanced or metastatic tumours eg, testicular carcinoma (palliative & curative polychemotherapy), ovary carcinoma (stages III & IV) & head & neck squamous cell epithelioma (palliative therapy). Small cell lung carcinoma. Advanced non-small cell lung carcinoma.

Adult & childn Monotherapy 50-120 mg/m² as single IV infusion over 6-8 hr every 3-4 wk or 15-20 mg/m²/day as IV infusion over 6-8 hr for 5 days every 3-4 wk. Combination chemotherapy Reduce dose to 20 mg/m² or more once every 3-4 wk. Small cell & non small cell lung carcinoma: 80 mg/m².

History of hypersensitivity to cisplatin or other platinum-containing compd. Preexisting renal or hearing impairment. Myelosuppressed & dehydrated patients Concurrent administration of yellow fever vaccine. Combination w/ phenytoin in prophylaxis. Lactation.

Monitor renal, hepatic & haematopoiesis functions & serum electrolytes, audiometry prior to, during & after administration. Perform neurologic exam at regular intervals. Avoid Al-containing IV sets, needles, catheters & syringes. May influence ability to drive vehicles & use machinery. May cause irreversible infertility. Avoid pregnancy during & for min of 6 mth following treatment.

Leukopenia, thrombocytopenia, anemia; anorexia, nausea, vomiting, diarrhea; hearing impairment; renal failure, nephrotoxicity, hyperuricemia; fever. Bone marrow failure; hyponatraemia. Sepsis; arrhythmia, bradycardia, tachycardia.

Potentiated nephrotoxic effect w/ cephalosporins, aminoglycosides, amphotericin B or contrast media. Potentially reduced renal elimination w/ cytostatic agents (eg, bleomycin & methotrexate). May increase renal toxicity of ifosfamide. Reduced blood lithium values w/ bleomycin & etoposide. May intensify nephrotoxicity w/ furosemide, hydralazine, diazoxide, & propranolol. Adjust dose of allopurinol, colchicine, probenecid or sulfinpyrazone as cisplatin increases serum uric acid conc. Increased protein excretion & hearing loss w/ ifosfamide. Potentiated ototoxic effect w/ aminoglycosides, loop diuretics. Yellow fever vaccine (contraindicated). Live vaccines (not recommended). Oral anticoagulants (regularly check INR). May mask ototoxicity symptoms w/ antihistamines, buclizine, cyclizine, loxapine, meclozine, phenothiazines, thioxanthenes or trimethobenzamides. May maintain serum conc of anticonvulsants at sub-therapeutic levels. May reduce absorption of phenytoin. May reduce clearance of paclitaxel. Increased myelosuppressive activity w/ myelosuppressives or radiation. Raynaud phenomenon may occur w/ bleomycin & vinblastine. Severe neurotoxic effects w/ docetaxel. Effectiveness may be diminished w/ chelating agents eg, penicillamine. Excessive immunosuppression w/ risk of lymphoproliferation w/ ciclosporin.

Cytotoxic Chemotherapy

L01XA01 - cisplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

POM